Germany · Delayed Price · Currency is EUR CompuGroup Medical SE & Co. KGaA Earnings Call Transcripts
Fiscal Year 2025
-
Q1 2025 saw modest revenue growth of 1% year over year, driven by recurring revenues, while one-time revenues declined. Adjusted EBITDA and EPS fell, but free cash flow improved significantly. Strategic partnership with CVC Capital Partners was finalized, and full-year guidance for low to mid-single-digit organic growth was confirmed.
Fiscal Year 2024
-
2024 saw a 2% organic revenue decline, but recurring revenues grew 5% to nearly 75% of total, with adjusted EBITDA at €225 million and free cash flow at €66 million. Strategic acquisitions and a new partnership with CVC set the stage for renewed growth in 2025.
-
An investment agreement with CVC Capital Partners includes a €22 per share tender offer, a 51% premium, aiming to take the company private while the founding family retains majority control. The offer is subject to regulatory approvals and a 17% minimum acceptance threshold.
-
Q3 2024 saw stable revenues with 6% growth in recurring revenues, offset by lower one-time revenues due to project delays. Operational improvements and AI-driven product launches supported margins, while guidance for 2024 remains cautious amid regulatory uncertainties.
-
H1 2024 revenues fell 6% year-over-year, prompting a downward revision of 2024 guidance for revenue, EBITDA, free cash flow, and EPS. Delays in regulatory projects and increased AI investments drove the cut, but recurring revenues remain strong and management expects improvement in H2.